With our partner Salesforce, unify sales, marketing and customer service. Accele your growth!
Endometriosis touches 10 % of women of childbearing ageeither 2.5 million people in France. This chronic disease, which causes disabling pain, fertility disorders and psychological impacts, is still poorly diagnosed and insufficiently taken care of. Faced with this observation, Lyv Healthcare develops a Digital therapy (DTX)a digital medical device allowing patients to better manage their symptoms. Lyv Endo is a certified application Digital medical device (DMN) CE of class I, which is based on A multidisciplinary approachaligned with the practices of expert centers. Designed with and for patients, it structures a personalized program around Five pillars :: education, physical activity, nutrition, mental well-being and support for intimate life.
Digital therapies, a new path for chronic diseases
The rise of Digital therapies (DTX) opens up new perspectives for the management of chronic diseases. The global DTX market is estimated at 9 billion euros by 2028with increasing adoption in pathologies such as diabetes, psychiatric disorders or cardiovascular disease.
The main issue lies in medical recognition and reimbursement of these solutions. In the United States, the FDA has already approved several DTX as therapeutic alternatives. In Europe, Digital medical devices are still struggling to be integrated into reimbursement systemsslowing down their large -scale adoption. Lyv Healthcare wants to change this dynamic by registering Lyv Endo in Early access devices such as Pecan (digital early management)first step towards supporting by social security.
The startup, founded in 2021 by Hélène Antier, Chloé Bonnet and Maïa Alexalineaims to Become a reference player in DTX in Europe, dedicated to the health of women. To accelerate its development, Lyv Healthcare announces a fundraising of funds 2.6 million euros in seed with Mutual impact, investing &+, Investing and Bee Impact Investing France, followed by Mgen and Business Angels.
